Veletri (Epoprostenol Sodium) Patent Expiration, LOE Window & CMS Spending
Veletri (Epoprostenol Sodium) by Johnson & Johnson: FDA Orange Book LOE 2027-03-15, 0 AB generics, $5.7M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Johnson & Johnson |
| FDA Application & Pathway | N022260 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2027-03-15 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $5.7M |
| 2024 Medicare Part D Spend | $606K |
| 2024 Medicaid Spend | $5.1M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 19.1% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.